Pluristem Therapeutics IncFind Ratings Reports
PLURISTEM THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased.
During the same period, stockholders' equity ("net worth") has decreased by 5.37% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||0.0||0.1|
|Net Income ($mil)||-7.2||-7.23|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||37.97||41.99|
|Total Assets ($mil)||49.99||54.44|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||0.0||-7403.16|
|Return on Assets||-44.68||-46.98|
|Return on Equity||-51.81||-56.14|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||80.08||71.04|
|Div / share||0.0||0.0|
|Book value / share||0.54||0.64|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||129472.0||253910.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 2.81 indicates valuation on par with the S&P 500 average of 2.81 and a significant discount versus the industry average of 11.16. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, PLURISTEM THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|PSTI NM||Peers 40.39||PSTI NM||Peers 21.72|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PSTI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PSTI's P/CF is negative making the measure meaningless.
|PSTI NM||Peers 122.62||PSTI NA||Peers 1.15|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PSTI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PSTI 2.81||Peers 11.16||PSTI 24.33||Peers -19.12|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PSTI is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PSTI is expected to have an earnings growth rate that significantly exceeds its peers.
|PSTI 41.13||Peers 425.82||PSTI 675.98||Peers 40.81|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PSTI is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
PSTI has a sales growth rate that significantly exceeds its peers.